LONDON – Anergis SA raised CHF18 million (US$19.6 million) in a Series A round to fund the development of allergy vaccines based on synthetic versions of natural allergens, which it said will be able to induce tolerance more quickly than is the case with de-sensitizing through the long-term administration of natural allergens. Read More
Not satisfied with merely providing early stage research support to fight cancer, the Multiple Myeloma Research Foundation has an "end-to-end" strategy for fostering drug development at every stage. The MMRF, headquartered in Norwalk, Conn., has served as midwife to four breakthrough therapies for multiple myeloma: Velcade, Thalomid, Revlimid and Doxil. Read More
Yuma Therapeutics Corp., of New York, received a $249,810 grant from the Alzheimer's Drug Discovery Foundation to develop small molecules against Alzheimer's. The award will fund work to develop Yuma's disease-modifying compounds designed to target neurofibrillary tangles resulting from abnormal forms of tau protein. Read More
The FDA has cleared an investigational new drug request from Evolva Holding SA, of Reinach, Switzerland, paving the way for a human trial of EV-077 to treat influenza. In preclinical testing, the candidate showed potential as prophylaxis and treatment of various viral infections, according to the company. Read More
Hospira Inc., of Lake Forest, Ill., elected F. Michael (Mike) Ball CEO and board member. Founding CEO Christopher B. Begley will assume the role of executive chairman. Read More
